Sartorius Stedim Biotech (CHIX:DIMP) ROCE %: 10.07% (As of Mar. 2026)


CHIX:DIMP Sartorius Stedim Biotech SA CHIX:DIMP
84 GF Score
Price €162.10
GF Value €207.88
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech ROCE %?

Sartorius Stedim Biotech CHIX:DIMP 84 ROCE % is 10.07% as of Mar. 2026. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €207.88 (Modestly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sartorius Stedim Biotech's annualized ROCE % for the quarter that ended in Mar. 2026 was 10.07%.

Sartorius Stedim Biotech  (CHIX:DIMp) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sartorius Stedim Biotech ROCE % Related Terms

Sartorius Stedim Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech ROCE % Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.26 33.10 9.59 5.23 7.38

Sartorius Stedim Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.75 6.72 7.97 4.36 10.07
CHIX:DIMP
84GF Score
Sartorius Stedim Biotech SA CHIX:DIMP
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech ROCE % Calculation

Sartorius Stedim Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=512.7/( ( (8256.4 - 938.8) + (7984 - 1412.1) )/ 2 )
=512.7/( (7317.6+6571.9)/ 2 )
=512.7/6944.75
=7.38 %

Sartorius Stedim Biotech's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=662.4/( ( (7984 - 1412.1) + (8189.8 - 1609.2) )/ 2 )
=662.4/( ( 6571.9 + 6580.6 )/ 2 )
=662.4/6576.25
=10.07 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 10.07% mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a ROCE % of 10.07% as of Mar. 2026.
Is Sartorius Stedim Biotech's ROCE % too high?
Sartorius Stedim Biotech's current ROCE % is 10.07%. The Medical Devices & Instruments industry median ROCE % is 2.23. Sartorius Stedim Biotech's value of 10.07% is 351.6% above this industry median. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's ROCE % compare to ISRG and BDX?
Sartorius Stedim Biotech's ROCE % of 10.07% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Sartorius Stedim Biotech's value of 10.07% is 351.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current ROCE % of 10.07% is 351.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current ROCE % is 10.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €207.88, compared to a current price of €162.10 — trading 22% below its estimated fair value. The current ROCE % is 10.07% and 351.6% above the Medical Devices & Instruments industry median of 2.23. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current ROCE % is 10.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €162.10 is trading 22% below its estimated GF Value™ of €207.88. GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.

Key valuation signals for CHIX:DIMP:

  • ROCE %: 10.07%
  • GF Value™: €207.88 vs. price of €162.10 (22% below fair value)
  • GF Score™: 84/100 with 5 warning signs
  • Industry Position: 351.6% above the Medical Devices & Instruments median

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score

Get the complete analysis for CHIX:DIMP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€162.10
Price
€207.88
GF Value